Catatonia in Nodding Syndrome and Lorazepam Treatment
Information source: Makerere University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Catatonia; Nodding Syndrome
Intervention: Lorazepam (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Makerere University Official(s) and/or principal investigator(s): Angelina Kakooza-Mwesige, MMed, Principal Investigator, Affiliation: Makerere University College of Health Sciences, Kampala, Uganda Dirk M Dhossche, MD, PhD, Study Director, Affiliation: University of Mississippi Medical Center, Jackson, USA
Summary
Nodding Syndrome is an enigmatic neuropsychiatric syndrome affecting children and
adolescents mostly in Eastern Africa. The symptoms of Nodding Syndrome and catatonia seem to
overlap. The researchers' objectives in this study were to investigate the presence and
types of catatonic symptoms in children with Nodding Syndrome and observe their response to
one or two doses of lorazepam, the first-line treatment for catatonia.
Clinical Details
Official title: Catatonia in Ugandan Children With Nodding Syndrome and Effects of Treatment With Lorazepam: A Pilot Study
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Primary outcome: A positive catatonia test (>50% reduction in catatonia symptoms and signs) on the responses of the children and adolescents with Nodding Syndrome and catatonia to test doses of oral Lorazepam.
Detailed description:
In this pilot study, the investigators examined a convenient sample of children and
adolescents with Nodding Syndrome (NS) for catatonic symptoms using standardized criteria.
The investigators also tested whether oral lorazepam (LZP) administered to those who
qualified to have pediatric catatonia would alleviate symptoms. This was a cross-sectional
descriptive study of catatonia in NS patients in Northern Uganda and an exploratory study of
using one or two doses of lorazepam as a catatonia test.
All the children with confirmed NS that had 2 or more of symptoms of catatonia were
recruited to undergo the catatonia test using oral Lorazepam EGĀ® (n. v. Eurogenerics s. a.
Brussels, Belgium) using the 1 mg formulation tablets. It was proposed to perform a
catatonia test using Lorazepam (LZP) as first choice medication, as this is the medication
that has been used most commonly in pediatric catatonia.
The amount of drug given was based on the weight of the child. The lower dose (0. 5 mg) was
used as starting dose for patients with <30 kg body weight, while the higher dose (1 mg) as
the starting dose for patients with >30 kg body weight.
A positive response to a catatonia test consisted of a reduction in catatonic symptoms, 30
or 60 minutes later, by at least 50% .Positive responses were documented by video footage
before and after administration of LZP.
If no response to the initial dose of LZP, was observed after one hour, a second
administration of the same medication at double the dose was given. Catatonia was again
assessed at 30 and 60 minutes thereafter. If no response was observed, the test was
considered negative.
Eligibility
Minimum age: 10 Years.
Maximum age: 21 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Children and adolescents with Nodding Syndrome as defined by the consensus definition
agreed upon in the international Nodding Syndrome research meeting held in Kampala,
Uganda July 2012.
2. Presence of two or more catatonic items on the Kampala Catatonia Panel.
3. Written informed consent from caregiver.
Exclusion Criteria:
1. Children and adolescents with Nodding Syndrome who had a history of having used a
benzodiazepine drug in the past 48 hours prior to intervention.
2. Children and adolescents with Nodding Syndrome who had a concurrent acute illness
(e. g febrile illness, pneumonia) at time of assessment.
Locations and Contacts
Additional Information
Related publications: Smith SL, Grelotti DJ, Fils-Aime R, Uwimana E, Ndikubwimana JS, Therosme T, Severe J, Dushimiyimana D, Uwamariya C, Bienvenu R, Alcindor Y, Eustache E, Raviola GJ, Fricchione GL. Catatonia in resource-limited settings: a case series and treatment protocol. Gen Hosp Psychiatry. 2015 Jan-Feb;37(1):89-93. doi: 10.1016/j.genhosppsych.2014.10.009. Epub 2014 Oct 30. Tibrewal P, Narayanaswamy J, Zutshi A, Srinivasaraju R, Math SB. Response rate of lorazepam in catatonia: a developing country's perspective. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1520-2. doi: 10.1016/j.pnpbp.2010.08.017. Epub 2010 Sep 8. Kakooza-Mwesige A, Wachtel LE, Dhossche DM. Catatonia in autism: implications across the life span. Eur Child Adolesc Psychiatry. 2008 Sep;17(6):327-35. doi: 10.1007/s00787-008-0676-x. Epub 2008 Apr 21. Review. Sejvar JJ, Kakooza AM, Foltz JL, Makumbi I, Atai-Omoruto AD, Malimbo M, Ndyomugyenyi R, Alexander LN, Abang B, Downing RG, Ehrenberg A, Guilliams K, Helmers S, Melstrom P, Olara D, Perlman S, Ratto J, Trevathan E, Winkler AS, Dowell SF, Lwamafa D. Clinical, neurological, and electrophysiological features of nodding syndrome in Kitgum, Uganda: an observational case series. Lancet Neurol. 2013 Feb;12(2):166-74. doi: 10.1016/S1474-4422(12)70321-6. Epub 2013 Jan 8. Dhossche DM. Decalogue of catatonia in autism spectrum disorders. Front Psychiatry. 2014 Nov 6;5:157. doi: 10.3389/fpsyt.2014.00157. eCollection 2014. Review.
Starting date: March 2013
Last updated: June 2, 2015
|